TipRanks on MSN4h
Crispr Therapeutics Faces Market Challenges Amidst BPCIA Biosimilar Risks
Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...
Crispr Therapeutics AG (CRSP) Receives a Buy from Chardan Capital
In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research ...
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...
CRISPR upgraded to hold by TD Cowen on limited downside
TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...
CRISPR stock rating raised to hold by TD Cowen, target steady
CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...
Crispr Therapeutics price target raised to $56 from $55 at Barclays
Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...